(S)-2-((S)-1-(Diphenylphosphanyl)piperidin-2-yl)-4-isopropyl-4,5-dihydrooxazole

Catalog No. :
ACYEOZ256
CAS No. :
2757084-44-7
Molecular Formula :
C23H29N2OP
Molecular Weight :
380.47

IUPAC Name:(S)-2-((S)-1-(diphenylphosphaneyl)piperidin-2-yl)-4-isopropyl-4,5-dihydrooxazole

(S)-2-((S)-1-(Diphenylphosphanyl)piperidin-2-yl)-4-isopropyl-4,5-dihydrooxazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$163.00Login to see priceIn stockInquiry
100mg97%$252.00Login to see priceIn stockInquiry
250mg97%$406.00Login to see priceIn stockInquiry
1g97%$1091.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(S)-2-((S)-1-(Diphenylphosphanyl)piperidin-2-yl)-4-isopropyl-4,5-dihydrooxazole
IUPAC Name(S)-2-((S)-1-(diphenylphosphaneyl)piperidin-2-yl)-4-isopropyl-4,5-dihydrooxazole
Molecular FormulaC23H29N2OP
Molecular Weight380.47
SMILESCC([C@@H]1N=C([C@H]2N(P(C3=CC=CC=C3)C4=CC=CC=C4)CCCC2)OC1)C
InChI KeyPQUUCDVLTJZOFT-YADHBBJMSA-N
SynonymPiperidine, 2-[(4S)-4,5-dihydro-4-(1-methylethyl)-2-oxazolyl]-1-(diphenylphosphino)-, (2S)-;(S)-2-((S)-1-(Diphenylphosphanyl)piperidin-2-yl)-4-isopropyl-4,5-dihydrooxazole;(2S)-2-[(4S)-4,5-Dihydro-4-(1-methylethyl)-2-oxazolyl]-1-(diphenylphosphino)piperidine
CAS No.2757084-44-7
PubChem CID163201303

Synthetic Route by SureRoute

1. ACYEOZ256 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACYEOZ256 route product structure diagram
    ACYEOZ2562757084-44-7 In Stock
Inquiry

2. ACYEOZ256 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYEOZ256 route product structure diagram
    ACYEOZ2562757084-44-7 In Stock
Inquiry

Comments (0)